Research News
Cancer drug shows promise for multiple sclerosis
BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7469 (Published 05 November 2012) Cite this as: BMJ 2012;345:e7469
Two manufacturer sponsored phase III trials suggest that alemtuzumab, an anti-CD52 monoclonal antibody that is licensed to treat leukaemia, may help control multiple sclerosis. Both trials lasted two years and compared alemtuzumab with interferon beta-1a, which is considered first line treatment. One trial looked at 563 patients who had not yet undergone treatment for multiple sclerosis, whereas the other trial looked at …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£23 / $37 / €30 (inc. VAT)
You can download a PDF version for your personal record.